Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $57M (up 7.8% year over year) with net income of $8M.
Q2 2026 key financials · XBRL
- Revenue
- $57M
- +7.8% YoY · +26.1% QoQ
- Net income
- $8M
- +39.9% YoY · +318.2% QoQ
- Operating margin
- 13.4%
- EPS (diluted)
- $0.15
- +25.0% YoY · +314.3% QoQ
Source: XBRL data from the PUMA BIOTECHNOLOGY, INC. (PBYI) Q2 2026 10-Q on SEC EDGAR. USD.
PUMA BIOTECHNOLOGY, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures
- Newly adopted Rule 10b5-1 plans allow directors to sell up to 117,843 shares
- Note Purchase Agreement amended April 16, 2026 with Athyrium Opportunities IV Co-Invest 1 LP
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PUMA BIOTECHNOLOGY, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.